PEOPLE ON THE MOVE
Immune Pharmaceuticals
Immune Pharmaceuticals has announced the appointment of Boris Shor as executive director of R&D and scientific partnerships.
In his new role, Shor will establishan immunology research laboratory within the Alexandria Center for Life Science at Immune’s headquarters in New York City. He will lead translational research efforts to support the development of the company's lead clinical stage candidate, bertilimumab, as well as the discovery and development of pipeline drugs utilizing NanomAbs, antibody nano-conjugates for the targeted delivery of cancer drugs.
Shor joins Immune from the Pfizer Oncology Research Unit where he helped develop antibody-drug conjugates (ADCs) for oncology.
After beginning his career with a PhD in Molecular and Cell Biology at the State University of New York, Shor completed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D before joining Pfizer.